Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Ventrus Plans Late-2013 NDA for Anal Fissure Topical Cream

Drug Industry Daily

Nov. 6, 2012 | Vol. 11 No. 218

Ventrus Plans Late-2013 NDA for Anal Fissure Topical Cream

Ventrus is planning on a late-2013 NDA for VEN-307, a cream to treat anal fissure pain, after completion of a second Phase III trial.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Lilly Halts Phase III Trial of Non-Hodgkin’s Lymphoma Candidate The Buzz FDA Urges Risk-Based Immunogenicity Assessments for Therapeutic Protein Products Biogen Idec Sees Positive Top-Line Results for Peginterferon Beta-1a in Multiple Sclerosis

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.